China, AstraZeneca

Despite China’s investigations into insurance fraud, allegedly illegal importation of unapproved drugs and improper ...
Guidance: For fiscal year 2024, AstraZeneca forecasts total revenue and core EPS to increase by a high-teens percentage, ...
Trump has threatened to slap a tariff of up to 60% on all goods imported to the U.S. from China. But Soriot called his ...
AstraZeneca Plc isn’t the only health-care company facing compliance questions in China as concern continued to swirl ...
AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...
AstraZeneca has focused on growing its sales in China for years, with Mr Wang credited for expanding the business since ...
AstraZeneca Plc started the week with a market valuation of about £171 billion ($222 billion). By the close on Thursday it ...
Not too long ago, pharmaceutical giant Astrazeneca reached a £200bn valuation—one of only a few London-listed FTSE 100 ...